ONCOLOGIC SAFETY OF LIPOFILLING IN POST MASTECTOMY BREAST CANCER PATIENTS – A RETROSPECTIVE MATCHED CASE-CONTROL STUDY susanna.kauhanen@hus.fi

225-03

ONCOLOGIC SAFETY OF LIPOFILLING IN POST MASTECTOMY BREAST CANCER PATIENTS – A RETROSPECTIVE MATCHED CASE-CONTROL STUDY

4

Finland

Oral only

Autologous fat transfer is a versatile tool to reconstruct the breast. Clinical studies increasingly attest to the oncological safety of lipofilling in breast cancer patients. We aimed to look at long-term disease free survival (DFS) and disease specific survival (DSS) in a homogenous group of patients having undergone full mastectomy and a delayed reconstruction with lipofilling alone.

Breast cancer patients undergoing full mastectomy between 1998 and 2015 at Helsinki University Hospital, and opting for delayed full reconstruction with large volume fat grafting alone in 3-4 settings comprised the study group (n=50). The control group (n= 145) consisted of case control matched patients (time point of cancer surgery, age and TNM classification) undergoing mastectomy without reconstruction. Kaplan Meyer and Mann Whitney U tests were used. Primary outcomes were DFS and DSS.

The mean age of lipofilling patients was 54y (range 39-74) and 53 (range 31-83) without lipofilling, p = 0.82. The mean follow-up time was 9.5 years (SD 4,8). The 5- and 10-year DFS was 100% and 92% (SD2%) respectively in women undergoing lipofilling and 92 % (SD5%) and 78 % (SD2%) for the controls (p=0.04). The 5-and 10-year DSS in the group with lipofilling was 100 % and 98% (SD 3%) and for the case control group 97% (SD3%) and 88% (SD 4%), p = 0,05.

No impact of large volume lipofilling was found on DFS and DSS in women with a history of breast cancer. Based on these data, post-mastectomy breast reconstruction with lipofilling is oncologically safe.